REPL PDUFA decision: a positive outcome, +9.4%

On May 12, 2026, RP1 — Replimune Group, Inc. (Non-Small Cell Lung Cancer (NSCLC)) reached its PDUFA decision. The result was a positive outcome, and the stock moved +9.4% in the window around the event. It had already run -14.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.